604 related articles for article (PubMed ID: 23091096)
41. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Juergens C; Weston C; Lewis I; Whelan J; Paulussen M; Oberlin O; Michon J; Zoubek A; Juergens H; Craft A
Pediatr Blood Cancer; 2006 Jul; 47(1):22-9. PubMed ID: 16572419
[TBL] [Abstract][Full Text] [Related]
42. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Bernstein ML; Devidas M; Lafreniere D; Souid AK; Meyers PA; Gebhardt M; Stine K; Nicholas R; Perlman EJ; Dubowy R; Wainer IW; Dickman PS; Link MP; Goorin A; Grier HE; ; ;
J Clin Oncol; 2006 Jan; 24(1):152-9. PubMed ID: 16382125
[TBL] [Abstract][Full Text] [Related]
43. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Felgenhauer J; Hawkins D; Pendergrass T; Lindsley K; Conrad EU; Miser JS
Med Pediatr Oncol; 2000 Jan; 34(1):29-38. PubMed ID: 10611582
[TBL] [Abstract][Full Text] [Related]
44. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
45. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC;
Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204
[TBL] [Abstract][Full Text] [Related]
46. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
[TBL] [Abstract][Full Text] [Related]
47. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Craft A; Cotterill S; Malcolm A; Spooner D; Grimer R; Souhami R; Imeson J; Lewis I
J Clin Oncol; 1998 Nov; 16(11):3628-33. PubMed ID: 9817284
[TBL] [Abstract][Full Text] [Related]
48. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
49. Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
DuBois SG; Grier HE
Nat Rev Clin Oncol; 2009 May; 6(5):251-3. PubMed ID: 19390548
[TBL] [Abstract][Full Text] [Related]
50. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
Deméocq F; Oberlin O; Benz-Lemoine E; Boilletot A; Gentet JC; Zucker JM; Behar C; Poutard P; Olive D; Brunat-Mentigny M
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S45-7. PubMed ID: 2667789
[TBL] [Abstract][Full Text] [Related]
51. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
52. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
53. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
54. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
Kolb EA; Kushner BH; Gorlick R; Laverdiere C; Healey JH; LaQuaglia MP; Huvos AG; Qin J; Vu HT; Wexler L; Wolden S; Meyers PA
J Clin Oncol; 2003 Sep; 21(18):3423-30. PubMed ID: 12972518
[TBL] [Abstract][Full Text] [Related]
55. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
56. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen U; Brennan B; Le Deley MC; Cozic N; van den Berg H; Bhadri V; Brichard B; Claude L; Craft A; Amler S; Gaspar N; Gelderblom H; Goldsby R; Gorlick R; Grier HE; Guinbretiere JM; Hauser P; Hjorth L; Janeway K; Juergens H; Judson I; Krailo M; Kruseova J; Kuehne T; Ladenstein R; Lervat C; Lessnick SL; Lewis I; Linassier C; Marec-Berard P; Marina N; Morland B; Pacquement H; Paulussen M; Randall RL; Ranft A; Le Teuff G; Wheatley K; Whelan J; Womer R; Oberlin O; Hawkins DS;
J Clin Oncol; 2019 Dec; 37(34):3192-3202. PubMed ID: 31553693
[TBL] [Abstract][Full Text] [Related]
57. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Ladenstein R; Pötschger U; Le Deley MC; Whelan J; Paulussen M; Oberlin O; van den Berg H; Dirksen U; Hjorth L; Michon J; Lewis I; Craft A; Jürgens H
J Clin Oncol; 2010 Jul; 28(20):3284-91. PubMed ID: 20547982
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
Mora J; de Torres C; Parareda A; Torner F; Galván P; Rodríguez E; Cardesa T; Salvador H; Suñol M; Huguet R; Cruz O
Pediatr Blood Cancer; 2011 Jul; 57(1):69-75. PubMed ID: 21384537
[TBL] [Abstract][Full Text] [Related]
59. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
60. Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.
Lucari B; Tallis E; Sutton VR; Porea T
Pediatr Hematol Oncol; 2023 May; 40(4):422-428. PubMed ID: 36125320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
